Australia, April 20th 2005: Visiomed Group Ltd (ASX:VSG) subsidiary InfaMed Ltd. announced today that they have commenced sales of the award winning and innovative children’s asthma product, Funhaler® in Australia. The Funhaler® is being distributed to pharmacies through the Advance Healthcare subsidiary, Cottman Australia.
The proprietary and patented Funhaler®, developed specifically to encourage children to take their asthma medication in accordance with clinical prescriptions, was granted TGA listing in Australia and FDA clearance in the US in January 2005. In March 2005 the Funhaler® was judged the best of the three inventions competing in the ABC programme, The New Inventors.
The Funhaler® (www.funhaler.com ) is an asthma spacer which incorporates in its design an incentive module such as a whistle and a spinning disk to help the children comply with taking their asthma medication. Independent, peer-reviewed clinical studies have shown that use of the Funhaler® increases compliance and delivery of asthma medication. Both children and their parents prefer the Funhaler® to other spacers and to the use of asthma medication "puffers" alone.
The device is modular, so the incentive module can be changed, and made of durable, heat-resistant plastic, so it can be thoroughly and easily cleaned.
Visiomed CEO, Dr William F. Dolphin said: "The release of the Funhaler® is a major step in helping children with respiratory ailments to improve their health outcome and get on with a normal, healthy and full life. We’re delighted that Cottman will be distributing this outstanding and innovative product to pharmacies throughout Australia." Cottman has committed to significant minimum purchases of Funhaler® units during the first year of distribution. Australia represents approximately 1-2% of the asthma market in the OECD member countries. There has been great interest in the Funhaler® in the USA, Japan, Italy, Germany and Spain and the company expects international release of the product in 1Q 2006.
About Visiomed Group Ltd
Visiomed (www.visiomed.com.au) develops and commercialises innovative medical devices. Apart from the Funhaler®, Visiomed also has the exclusive world wide licences for computer-based smart systems for the imaging and diagnosis of diseases other than dermatological conditions. The company is utilising its intellectual property to develop the microEYE imaging system as an aid in the screening and diagnosis of eye diseases such as cataract, glaucoma, trachoma, macular degeneration and diabetic retinopathy.
About the Funhaler®
The Funhaler® is a children’s incentive spacer for the effective delivery of asthma drugs, developed in Australia. It incorporates toys that respond to inhalation and was designed to encourage children to take their asthma medication. The Funhaler® is covered by international patents issued and pending.
Clinical studies involving the Funhaler® are currently under way with support of a $1 million grant from the US National Institutes of Health. The Funhaler® is protected in multiple countries by broad coverage patents issued and pending (Reference: USPTO: 6,578,571). This coverage already extends to protection of a wide range of alternative incentive toy modules in the Funhaler circuit.
About Advance Healthcare Group Limited
Advance Healthcare Group Limited (ASX: AHG) has a unique and innovative medication management and supply business (Pharmeasy®) with substantial national growth potential together with its well-established pharmaceutical and medical surgical distribution business (Cottman Australia). The strategic focus of the Group continues to be to grow the well established pharmaceutical and medical distribution business of Cottman Australia, with particular focus on high margin products (current Australian turnover approximately $100 million). Advance also continues to develop its innovative national approach to medication management and supply home delivery service, the Pharmeasy® direct to consumer pharmaceutical health wellbeing and beauty business.
For further information, please contact Visiomed’s CEO Dr William Dolphin on (08) 9321 2712
For media enquiries please contact Rebecca Christie, Buchan (02) 9237 2800 or 0417 382 391.